CL2022002517A1 - Formulaciones de anticuerpos anti protofibrillas aß de alta concentración y métodos de uso de las mismas - Google Patents

Formulaciones de anticuerpos anti protofibrillas aß de alta concentración y métodos de uso de las mismas

Info

Publication number
CL2022002517A1
CL2022002517A1 CL2022002517A CL2022002517A CL2022002517A1 CL 2022002517 A1 CL2022002517 A1 CL 2022002517A1 CL 2022002517 A CL2022002517 A CL 2022002517A CL 2022002517 A CL2022002517 A CL 2022002517A CL 2022002517 A1 CL2022002517 A1 CL 2022002517A1
Authority
CL
Chile
Prior art keywords
methods
high concentration
protofibril antibody
antibody formulations
concentration anti
Prior art date
Application number
CL2022002517A
Other languages
English (en)
Spanish (es)
Inventor
Nobuo Yoshida
Naomi Sakuramoto
Takahisa Sakaguchi
Hirokazu Kito
Takahiro Ozawa
Anjali Joshi
Yung Yueh Hsu
Pierre Souillac
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of CL2022002517A1 publication Critical patent/CL2022002517A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
CL2022002517A 2020-03-20 2022-09-14 Formulaciones de anticuerpos anti protofibrillas aß de alta concentración y métodos de uso de las mismas CL2022002517A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062992746P 2020-03-20 2020-03-20
US202063027263P 2020-05-19 2020-05-19

Publications (1)

Publication Number Publication Date
CL2022002517A1 true CL2022002517A1 (es) 2023-03-24

Family

ID=75746958

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2022002517A CL2022002517A1 (es) 2020-03-20 2022-09-14 Formulaciones de anticuerpos anti protofibrillas aß de alta concentración y métodos de uso de las mismas
CL2024003428A CL2024003428A1 (es) 2020-03-20 2024-11-08 "formulaciones de anticuerpos anti protofibrillas aß de alta concentración y métodos de uso de las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2024003428A CL2024003428A1 (es) 2020-03-20 2024-11-08 "formulaciones de anticuerpos anti protofibrillas aß de alta concentración y métodos de uso de las mismas.

Country Status (27)

Country Link
US (1) US20230183328A1 (https=)
EP (2) EP4121007B1 (https=)
JP (2) JP7689141B2 (https=)
KR (1) KR20220156534A (https=)
CN (1) CN115315251A (https=)
AU (1) AU2021238951A1 (https=)
BR (1) BR112022018766A2 (https=)
CA (1) CA3174778A1 (https=)
CL (2) CL2022002517A1 (https=)
CO (1) CO2022012916A2 (https=)
DK (1) DK4121007T3 (https=)
ES (1) ES3041762T3 (https=)
FI (1) FI4121007T3 (https=)
HR (1) HRP20251087T1 (https=)
HU (1) HUE072937T2 (https=)
IL (2) IL295383B1 (https=)
LT (1) LT4121007T (https=)
MA (1) MA59082B1 (https=)
MD (1) MD4121007T2 (https=)
MX (1) MX2022011101A (https=)
PH (1) PH12022552172A1 (https=)
PL (1) PL4121007T3 (https=)
PT (1) PT4121007T (https=)
RS (1) RS67249B1 (https=)
SI (1) SI4121007T1 (https=)
SM (1) SMT202500350T1 (https=)
WO (1) WO2021186245A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230039734A (ko) 2020-07-23 2023-03-21 오타이르 프로테나 리미티드 항-Aβ 항체
AU2022307687A1 (en) 2021-07-09 2024-01-04 Eisai R&D Management Co., Ltd. Biomarkers for alzheimer's disease treatment
AU2022439338A1 (en) 2022-02-02 2024-08-15 Eisai R&D Management Co., Ltd. Methods of treatment using p-tau181 level
JP2025539394A (ja) 2022-11-28 2025-12-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 タウｐｅｔレベルを使用する治療の方法
KR20260022396A (ko) 2023-06-09 2026-02-19 에자이 알앤드디 매니지먼트 가부시키가이샤 항-Aβ 프로토피브릴 항체를 사용한 치료 방법
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CN118370815A (zh) 2017-08-22 2024-07-23 渤健马萨诸塞州股份有限公司 含有抗β淀粉样蛋白抗体的药物组合物
US20210324056A1 (en) 2018-07-24 2021-10-21 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease

Also Published As

Publication number Publication date
PT4121007T (pt) 2025-09-25
LT4121007T (lt) 2025-09-25
BR112022018766A2 (pt) 2022-11-01
CA3174778A1 (en) 2021-09-23
EP4121007B1 (en) 2025-07-02
IL295383B1 (en) 2026-04-01
HUE072937T2 (hu) 2025-12-28
RS67249B1 (sr) 2025-10-31
TW202200201A (zh) 2022-01-01
KR20220156534A (ko) 2022-11-25
JP2023518066A (ja) 2023-04-27
PH12022552172A1 (en) 2023-12-11
FI4121007T3 (fi) 2025-09-11
CN115315251A (zh) 2022-11-08
EP4121007A1 (en) 2023-01-25
EP4252777A9 (en) 2024-03-06
MX2022011101A (es) 2022-10-03
PL4121007T3 (pl) 2025-11-03
JP2025111516A (ja) 2025-07-30
WO2021186245A1 (en) 2021-09-23
MA59082B1 (fr) 2025-09-30
ES3041762T3 (en) 2025-11-14
SMT202500350T1 (it) 2025-11-10
CL2024003428A1 (es) 2025-04-11
JP7689141B2 (ja) 2025-06-05
HRP20251087T1 (hr) 2025-11-07
SI4121007T1 (sl) 2025-10-30
CO2022012916A2 (es) 2022-09-20
IL295383A (en) 2022-10-01
AU2021238951A1 (en) 2022-10-20
IL326613A (en) 2026-04-01
EP4252777A3 (en) 2024-01-24
DK4121007T3 (da) 2025-09-22
US20230183328A1 (en) 2023-06-15
MD4121007T2 (ro) 2025-11-30
EP4252777A2 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
CL2022002517A1 (es) Formulaciones de anticuerpos anti protofibrillas aß de alta concentración y métodos de uso de las mismas
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
CO2019008986A2 (es) Derivados de tirosinamida como inhibidores de rho-quinasa
CL2023003965A1 (es) Inhibidores cdk2.
MX2021006552A (es) Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita.
MX387723B (es) Composición farmacéutica que comprende bromuro de glicopirronio, propionato de fluticasona y 1,1-difluoroetano.
MX2017015521A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
MX2022004143A (es) Compuesto que tiene actividad inhibidora de brd4, su método de preparación y su uso.
AR115721A1 (es) Anticuerpos que comprenden un polipéptido insertado en la región marco 3
EA201792487A1 (ru) Композиции гидроксипропил-бета-циклодекстринов и способы
AR132698A1 (es) DERIVADOS ESPIRO COMO INHIBIDORES DE LA HELICASA TIPO RecQ DEL SÍNDROME DE WERNER (WRN)
AR122352A1 (es) Un esteroide c21-n-pirazolilo 19-nor c3,3 disustituido y métodos de uso de este
MX2021005839A (es) Antagonistas del receptor de adenosina aminotriazolopirimidina y aminotriazolopirazina sustituidos, composiciones farmaceuticas y su uso.
CL2023002871A1 (es) Composiciones nasales que comprenden alcaftadina
CU20090007A6 (es) Un compuesto farmacéutico y un proceso del mismo
MX2019003097A (es) Composicion farmaceutica.
CL2023002446A1 (es) Inhibidores de enzimas
CR20250060A (es) Anticuerpos anti monometil auristatina y fragmentos de anticuerpos.
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.
AU2018260628A1 (en) Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
BR112022016960A2 (pt) Uso de análogos de ciclosporina para tratamento de câncer
MX2021013347A (es) Metodo para tratar el dolor asociado con endometriosis mediante el uso de un compuesto de diaminopirimidina.
MX2021012782A (es) El uso de polivinilpirrolidona (pvp) de bajo peso molecular para reducir la viscosidad de formulaciones de proteinas de alta concentracion.
MX2017014301A (es) Composiciones y metodos para el tratamiento o prevencion de hipertension pulmonar.